-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Ev5Fk3tqHp5RjPriH7mJ8tMSX2j+tgd9v/y8HkCYDDvxCPRsd5+3vw3efnVIxQnt
 fRvIZMz1WdoDQiQLj8ihVQ==

<SEC-DOCUMENT>0001414163-09-000002.txt : 20090511
<SEC-HEADER>0001414163-09-000002.hdr.sgml : 20090511
<ACCEPTANCE-DATETIME>20090511171832
ACCESSION NUMBER:		0001414163-09-000002
CONFORMED SUBMISSION TYPE:	D
PUBLIC DOCUMENT COUNT:		1
ITEM INFORMATION:		Rule 506
FILED AS OF DATE:		20090511
DATE AS OF CHANGE:		20090511
EFFECTIVENESS DATE:		20090511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Altheus Therapeutics Inc
		CENTRAL INDEX KEY:			0001414163
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		D
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	021-109372
		FILM NUMBER:		09816216

	BUSINESS ADDRESS:	
		STREET 1:		755 Research Parkway
		STREET 2:		Suite 435
		CITY:			Oklahoma City
		STATE:			OK
		ZIP:			73104
		BUSINESS PHONE:		(405) 319-8177

	MAIL ADDRESS:	
		STREET 1:		755 Research Parkway
		STREET 2:		Suite 435
		CITY:			Oklahoma City
		STATE:			OK
		ZIP:			73104
</SEC-HEADER>
<DOCUMENT>
<TYPE>D
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<edgarSubmission>

    <schemaVersion>X0301</schemaVersion>

    <submissionType>D</submissionType>

    <testOrLive>LIVE</testOrLive>

    <primaryIssuer>
        <cik>0001414163</cik>
        <entityName>Altheus Therapeutics Inc</entityName>
        <issuerAddress>
            <street1>755 Research Parkway</street1>
            <street2>Suite 435</street2>
            <city>Oklahoma City</city>
            <stateOrCountry>OK</stateOrCountry>
            <zipCode>73104</zipCode>
        </issuerAddress>
        <issuerPhoneNumber>(405) 319-8180</issuerPhoneNumber>
        <issuerPreviousNameList>
            <value>None</value>
        </issuerPreviousNameList>
        <jurisdictionOfInc>DE</jurisdictionOfInc>
        <entityType>Corporation</entityType>
        <yearOfInc>
            <withinFiveYears>true</withinFiveYears>
            <value>2006</value>
        </yearOfInc>
    </primaryIssuer>

    <relatedPersonsList>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Richard</firstName>
                <middleName>F</middleName>
                <lastName>Harty, MD</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>2700 Wilshire Blvd.</street1>
                <street2></street2>
                <city>Oklahoma City</city>
                <stateOrCountry>OK</stateOrCountry>
                <zipCode>73116</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Executive Officer</relationship>
                <relationship>Promoter</relationship>
            </relatedPersonRelationshipList>
            <relationshipClarification></relationshipClarification>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Brian</firstName>
                <middleName>L</middleName>
                <lastName>Clevinger</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>c/o Prolog Ventures, LLC</street1>
                <street2>7733 Forsyth Blvd., Suite 1440</street2>
                <city>St. Louis</city>
                <stateOrCountry>MO</stateOrCountry>
                <zipCode>63105</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Executive Officer</relationship>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
            <relationshipClarification></relationshipClarification>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Douglas</firstName>
                <middleName>A</middleName>
                <lastName>Branch</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>101 N. Robinson 13th Floor</street1>
                <street2>Corporate Tower</street2>
                <city>Oklahoma City</city>
                <stateOrCountry>OK</stateOrCountry>
                <zipCode>73102</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Executive Officer</relationship>
            </relatedPersonRelationshipList>
            <relationshipClarification></relationshipClarification>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>William</firstName>
                <middleName></middleName>
                <lastName>Paiva</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>211 N. Robinson Suite 1910</street1>
                <street2></street2>
                <city>Oklahoma City</city>
                <stateOrCountry>OK</stateOrCountry>
                <zipCode>73102</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
            <relationshipClarification></relationshipClarification>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Alpha</firstName>
                <middleName>BioPartners,</middleName>
                <lastName>Inc.</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>2500 Faber Place</street1>
                <street2></street2>
                <city>Palo Alto</city>
                <stateOrCountry>CA</stateOrCountry>
                <zipCode>94303</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Promoter</relationship>
            </relatedPersonRelationshipList>
            <relationshipClarification></relationshipClarification>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Thomas</firstName>
                <middleName>L</middleName>
                <lastName>Shoaf</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>Stifel, Nicolaus Company, Incorporated</street1>
                <street2>One Financial Plaza, 501 North Broadway</street2>
                <city>St. Louis</city>
                <stateOrCountry>MO</stateOrCountry>
                <zipCode>63102</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
            <relationshipClarification></relationshipClarification>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>James</firstName>
                <middleName></middleName>
                <lastName>Schoeneck</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>Brain Cells</street1>
                <street2>10835 Road To The Cure, Suite 150</street2>
                <city>San Diego</city>
                <stateOrCountry>CA</stateOrCountry>
                <zipCode>92121</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
            <relationshipClarification></relationshipClarification>
        </relatedPersonInfo>
    </relatedPersonsList>

    <offeringData>
        <industryGroup>
            <industryGroupType>Biotechnology</industryGroupType>
        </industryGroup>
        <issuerSize>
            <revenueRange>No Revenues</revenueRange>
        </issuerSize>
        <federalExemptionsExclusions>
            <item>06</item>
        </federalExemptionsExclusions>
        <typeOfFiling>
            <newOrAmendment>
                <isAmendment>false</isAmendment>
            </newOrAmendment>
            <dateOfFirstSale>
                <value>2009-05-01</value>
            </dateOfFirstSale>
        </typeOfFiling>
        <durationOfOffering>
            <moreThanOneYear>false</moreThanOneYear>
        </durationOfOffering>
        <typesOfSecuritiesOffered>
            <isDebtType>true</isDebtType>
            <isOptionToAcquireType>true</isOptionToAcquireType>
        </typesOfSecuritiesOffered>
        <businessCombinationTransaction>
            <isBusinessCombinationTransaction>false</isBusinessCombinationTransaction>
            <clarificationOfResponse></clarificationOfResponse>
        </businessCombinationTransaction>
        <minimumInvestmentAccepted>489</minimumInvestmentAccepted>
        <salesCompensationList></salesCompensationList>
        <offeringSalesAmounts>
            <totalOfferingAmount>1200000</totalOfferingAmount>
            <totalAmountSold>500062</totalAmountSold>
            <totalRemaining>699938</totalRemaining>
            <clarificationOfResponse>This transaction will close in 3 different rounds.  The closing of the 2nd round of approximately $20,800 is contingent upon investors exercising their right of first refusal.  The $679,149.71 3rd round is contingent upon certain milestones being met.</clarificationOfResponse>
        </offeringSalesAmounts>
        <investors>
            <hasNonAccreditedInvestors>false</hasNonAccreditedInvestors>
            <totalNumberAlreadyInvested>4</totalNumberAlreadyInvested>
        </investors>
        <salesCommissionsFindersFees>
            <salesCommissions>
                <dollarAmount>0</dollarAmount>
            </salesCommissions>
            <findersFees>
                <dollarAmount>0</dollarAmount>
            </findersFees>
            <clarificationOfResponse></clarificationOfResponse>
        </salesCommissionsFindersFees>
        <useOfProceeds>
            <grossProceedsUsed>
                <dollarAmount>50000</dollarAmount>
                <isEstimate>true</isEstimate>
            </grossProceedsUsed>
            <clarificationOfResponse></clarificationOfResponse>
        </useOfProceeds>
        <signatureBlock>
            <authorizedRepresentative>false</authorizedRepresentative>
            <signature>
                <issuerName>Altheus Therapeutics Inc</issuerName>
                <signatureName>Douglas A. Branch</signatureName>
                <nameOfSigner>Douglas A. Branch</nameOfSigner>
                <signatureTitle>Secretary</signatureTitle>
                <signatureDate>2009-05-11</signatureDate>
            </signature>
        </signatureBlock>
    </offeringData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----